Clinical trials: Glucagon
Obesity, Overweight
Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.
- Trial name
- NCT07908316
- Testing
- Maridebart cafraglutide
- Where
- 9 sites in United States
- Volunteers
- 180 people
- Sponsor
- Amgen
Obesity Morbid, Multimorbidity
Semaglutide and Physical Activity for Obesity and Multimorbidity
The aim of this observational study is to explore and describe changes in cardiometabolic health, physical activity, physical capacity, and wellbeing during interdisciplinary Semaglutide-based weight loss treatment in patients…
- Conditions
- Obesity Morbid, Multimorbidity, Obesity
- Trial name
- NCT06234111
- Testing
- Semaglutide 2.4 mg, total diet replacement, behavioural intervention
- Where
- Denmark
- Volunteers
- 35 people
- Sponsor
- Hvidovre University Hospital
Asthma
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
This is a randomized placebo-controlled trial of semaglutide, an FDA-approved therapy for the treatment of type 2 diabetes mellitus and obesity, in adults with symptomatic asthma despite the use of inhaled steroids and with…
- Trial name
- GATA-3 (NCT05254314)
- Testing
- Semaglutide Pen Injector 2.4mg weekly
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Vanderbilt University Medical Center
Diabetes Mellitus, Type 2
Low dosE GlibENclamide in Diabetes Part A
Diabetes is a chronic condition that affects 1 in 16 people in the UK, and leads to difficulty controlling blood sugar levels. This is due to an imbalance between two main hormones: insulin, which lowers blood sugar, and…
- Trial name
- LEGEND-A (NCT02830048)
- Testing
- Glibenclamide
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University of Oxford
Hypoglycemia
Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons
BIOD-961 is a dry powder formulation of glucagon intended for use in a device that mixes (reconstitutes) the powder with liquid to make it easier for users to treat patients with severe hypoglycemia.
- Trial name
- NCT02403648
- Testing
- BIOD-961, Lilly Glucagon, Novo Glucagon
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Biodel
Obesity or Overweight
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
- Trial name
- NCT07575399
- Testing
- Maridebart Cafraglutide
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Amgen
Type 2 Diabetes Mellitus
Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion
We want to investigate how lack of glucagon suppression during an oral glucose tolerance test in patients with type 2 diabetes contributes to patients postprandial hyperglycemia.
- Trial name
- EGP_Glucagon (NCT02010827)
- Testing
- isoglycemic intravenous glucose infusion and Glucagon infusion, day C, Oral glucose tolerance test, day A, intravenous iv glucose infusion, day B
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus, Obesity
Study of the Gut Hormone Analogue G3215 in Adult Subjects
A randomised, placebo controlled Phase I study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of G3215 in adult subjects.
- Trial name
- NCT02692040
- Testing
- G3215
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Diabetes, Heart Failure
The Effects of Neprilysin on Glucagon-like Peptide-1
In the current study we wish to investigate the effects on glucagon-like peptide-1 (GLP-1) of a neprilysin inhibitor
- Trial name
- NEP (NCT03717688)
- Testing
- Entresto, Sitagliptin 100mg
- Where
- Denmark
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Radiation Enteritis
Plasma GLP-2 Dynamics and Acute Radiation Enteritis After Abdominopelvic Radiotherapy
This prospective observational study will enroll 50 adults who are scheduled to receive radiotherapy to the abdomen or pelvis. The study will not assign any additional treatment or change routine clinical care.
- Trial name
- NCT07759258
- Testing
- Abdominopelvic Radiotherapy
- Volunteers
- 50 people
- Sponsor
- Wang Xinying
Critically Ill, Hypoglycemia
The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients
The goal of this present proposal is to examine the efficacy of GLP-1 administered to control blood glucose in critically ill patients.
- Trial name
- NCT00798590
- Testing
- Glucagon-Like Peptide-1, Saline
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
NAFLD, Diabetes
GLP-1 RA on Liver OMICS in MASLD
In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue.
- Conditions
- NAFLD, Diabetes, Obesity
- Trial name
- OMICS in MASLD (NCT06982378)
- Testing
- GLP-1 receptor agonist
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Monoclonal Gammopathies, Overweight
Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat
The purpose of this research study is to learn about the effect of Liraglutide (Victoza) on the fat of the heart and some fat cells in blood.
- Conditions
- Monoclonal Gammopathies, Overweight, Obesity
- Trial name
- NCT02920190
- Testing
- Liraglutide
- Sponsor
- University of Miami
Glucose Metabolism Disorders
Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines
Investigation of GLP-1 signalling in the glucose-lowering effect of increased carbohydrate content in the distal small intestines induced by alpha-glucosidase inhibition during meal ingestion in patients with type 2 diabetes
- Trial name
- AlfaEx (NCT03241303)
- Testing
- Acarbose, Exendin (9-39)
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Normal Healthy Volunteer, Safety After Oral Intake
A Research Study to Evaluate BLX-7006 in Healthy Adults
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection.
- Trial name
- NCT07140055
- Testing
- BLX-7006
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Type 2 Diabetes Mellitus, Steroids
Incretin Physiology Associated With Steroid Hormone Treatment
The purpose of this study is to evaluate whether the reduced incretin effect and the paradoxical glucagon responses during oral glucose ingestion and isoglycaemic iv glucose infusion observed in patients with type 2 diabetes are…
- Trial name
- NCT00713440
- Testing
- Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Glostrup University Hospital, Copenhagen
Type 1 Diabetes Mellitus
A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia
Primary Objective: To assess the pharmacodynamic response (PD) of a single subcutaneous (SC) dose of SAR438544 versus recombinant glucagon in type 1 diabetes mellitus (T1DM) patients under induced hypoglycemia.
- Trial name
- NCT02635243
- Testing
- SAR438544, r-glucagon, insulin
- Sponsor
- Sanofi
Diabetes Mellitus Type 2
The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion
Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus).
- Trial name
- NCT02796950
- Testing
- Acipimox
- Where
- Denmark
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Ischemic Stroke, Transient Ischemic Attack
Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus
The purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1 (GLP-1) analogue liraglutide in the treatment of acute minor stroke (National Institute of Health stroke scale, NIHSS ≤ 3) or high-risk…
- Conditions
- Ischemic Stroke, Transient Ischemic Attack, Type 2 Diabetes Mellitus
- Trial name
- LAMP (NCT03948347)
- Testing
- Liraglutide
- Where
- China
- Volunteers
- 1,708 people
- Sponsor
- First Affiliated Hospital of Jinan University
T2DM, Type 2 Diabetes Mellitus
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
The main purpose of this study is to investigate the efficacy and safety of XW003 versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by diet and exercise alone
- Trial name
- NCT05680155
- Testing
- Ecnoglutide
- Where
- China
- Volunteers
- 211 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.